Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model 

Slides:



Advertisements
Similar presentations
Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion  Ajay Kher, MD, Kirstan.
Advertisements

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 
Stephen R. Broderick, MD, MPHS 
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis-inducing.
Prediction of severe acute kidney injury after pediatric cardiac surgery with the use of novel biomarkers: A new trend in clinical research and risk stratification 
A meta-analysis of comparative studies of endovascular versus open repair for blunt thoracic aortic injury  Hisato Takagi, MD, PhD, Norikazu Kawai, MD,
De Novo Ceramide Synthesis Participates in the Ultraviolet B Irradiation-Induced Apoptosis in Undifferentiated Cultured Human Keratinocytes  Yoshikazu.
Ultrasound, endoscopy, and the recurrent nerve
Neel R. Sodha, MD, Frank W. Sellke, MD 
Murray H. Kwon, MD  The Journal of Thoracic and Cardiovascular Surgery 
Intrinsic cardiac stem cells are essential for regeneration
Philip A. Rascoe, MD, Xiaobo Cao, MD, Jonathan C. Daniel, MD, Steven D
Abracadabra I, II…HeartMate 3?
Victor van Berkel, MD, PhD 
Glutamine protects articular chondrocytes from heat stress and NO-induced apoptosis with HSP70 expression  H. Tonomura, M.D., K.A. Takahashi, M.D., Ph.D.,
Application of a neuroscience research model to study neuroprotection in children with congenital heart disease  Nobuyuki Ishibashi, MD, Richard A. Jonas,
How should we treat air leaks?
Ibuprofen for neuroprotection after cerebral ischemia
BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non- small Cell Lung Carcinoma In Vitro  Wenyan Li, MD, PhD, Bo Li, MD,
Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model  Yusuke Iwata, MD, Toru Okamura, MD, Nobuyuki Ishibashi, MD,
Bigger The Journal of Thoracic and Cardiovascular Surgery
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids  Hongyi Lei, MD,
The lord of the rings  Antonio Miceli, MD, PhD 
Rodent brain slice model for the study of white matter injury
The unintended consequences in clinical research
Leonard M. Rademakers, MD, Paul F. Gründeman, MD, PhD, Robert W
Support Your Specialty
The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery  Vinay Badhwar, MD  The Journal of Thoracic and.
It's not “just a shunt” but sometimes it should be…
Military surgeons just want to have fun
Do we need a bibliometrician to know which way the wind is blowing?
A first start for lung transplantation?
Stephen R. Broderick, MD, MPHS 
Get it right the first time
Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005  Scott D. Barnett, PhD,
Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD 
Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon
Instrumental variable methods in clinical research
A fate worse than death  Jennifer S. Lawton, MD 
Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling  Alessandro Brunelli, MD, Gaetano Rocco, MD 
Commentary: Do the right thing! Ethical versus legal
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Prognosis and “granularity”: Building on staging foundations?
Shunt right or left? Decision 2016
Syphilitic aortitis: The bigger picture
The origins of open heart surgery at the University of Minnesota 1951 to 1956  Richard A. DeWall, MD  The Journal of Thoracic and Cardiovascular Surgery 
Bryan M. Burt, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
The future of cardiac surgery training: A survival guide
Apparently, size matters…in congenital heart disease and brain injury
Bicuspid aortopathy: Seeing the forest for the trees
Ralph E. Delius, MD  The Journal of Thoracic and Cardiovascular Surgery 
Should it stay or should it go?
The Journal of Thoracic and Cardiovascular Surgery
“The more things change…”: The challenges ahead
Toll-like receptor 4 inhibition attenuates ischemia-reperfusion injury in rats: Will it work in human beings?  Chadrick E. Denlinger, MD  The Journal.
Managing conflicts of interest
Aritoshi Hattori, MD, Kenji Suzuki, MD 
Ryan R. Davies, MD  The Journal of Thoracic and Cardiovascular Surgery 
More than vital: Who bears the burden?
Respect the aorta The Journal of Thoracic and Cardiovascular Surgery
Preoperative PFTs: The answer is blowing in the wind
Of mice and men… The Journal of Thoracic and Cardiovascular Surgery
Spinal cord protection via alpha-2 agonist-mediated increase in glial cell-line–derived neurotrophic factor  Kirsten A. Freeman, MD, David A. Fullerton,
Samuel Kim, MD  The Journal of Thoracic and Cardiovascular Surgery 
Carl L. Backer, MD, Bradley S. Marino, MD, MPP, MSCE 
Journal changes and initiatives
Zone zero thoracic endovascular aortic repair is all about “location, location, location”  Kevin L. Greason, MD  The Journal of Thoracic and Cardiovascular.
Presentation transcript:

Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model  Zhaohui Lu, MD, Ludmila Korotcova, MD, Akira Murata, MD, Nobuyuki Ishibashi, MD, Richard A. Jonas, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 147, Issue 6, Pages 1939-1945 (June 2014) DOI: 10.1016/j.jtcvs.2013.09.054 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Aprotinin, but not lysine analogs, are neuroprotective against glutamatergic excitotoxicity. A-D, Mixed cortical culture at 24 hours after Sham wash (A), and Sham wash with clinical dose TXA (B) EACA (C) and aprotinin (D). E-H, Mixed cortical culture after 24-hour exposure with 12.5 μM NMDA (E), and 12.5 μM NMDA with clinical dose TXA (F) EACA (G) and aprotinin (H). I, Percentage of cell death at 24 hours after 12.5 μM NMDA exposure with TXA, EACA, and aprotinin. Neural cell death was identified by LDH assay measuring LDH levels in bathing medium in cultures.4 Low, clinical, and high doses of aprotinin reduced neuronal death from 70% to 56%, 39%, and 31%, respectively (F = 104.6, P < .0001). J, Percentage cell death at 24 hours after 12.5 μM NMDA exposure with clinical doses of TXA, EACA, and aprotinin compared with 12.5 μM NMDA alone. There were no significant changes in TXA (+8%, P = .11) and EACA (−3%, P = .45). A clinical dose of aprotinin significantly reduced cell death by −31% on average (P < .0001). *P < .001 versus 12.5 μM NMDA by ANOVA with Bonferroni comparisons. Data are shown as means ± standard error of the mean (n = 12). NMDA, N-Methyl-d-aspartic acid; EACA, ε-aminocaproic acid; TXA, tranexamic acid. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 1939-1945DOI: (10.1016/j.jtcvs.2013.09.054) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Aprotinin prevents serum deprivation (SD)–induced apoptosis in cortical neurons. A, Percentage of Trypan Blue positive cells at 24 hours after SD. Ten percent cell death in the control supports a technical consistency in our study.35 Aprotinin at 50, 100 and 200 kIU/mL decreased the percentage of Trypan Blue positive cells from 75% to 60%, 37% and 34%, respectively. B, Cell viability using the MTT assay after 24 hours SD. Aprotinin at 100 and 200 kIU/mL significantly increased the viability compared with no aprotinin (P < .05). There was no significant difference between no aprotinin and 50 kIU/mL aprotinin. C-G, Images with Hoechst 33258 staining at 24 hours after sham wash (C) and after SD with aprotinin at the concentration of 0 (D), 50 (E), 100 (F), and 250 kIU/mL (G). *P < .05, **P < .01, ***P < .001 versus aprotinin 0 kIU/mL by ANOVA with Bonferroni comparisons. Data are shown as means ± standard error of the mean (n = 8). AP, Aprotinin. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 1939-1945DOI: (10.1016/j.jtcvs.2013.09.054) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Aprotinin inhibits apoptosis via the mitochondrial pathway and 250 kIU/mL is an optimal dose for protection. A and B, Caspase 3/7 and 9 activity after 24 hours serum deprivation (SD) in primary cortical neuron culture. C-E, Images after 24 hours SD in a neuron culture without aprotinin. F, Percentage of caspase 3–positive cells at 24 hours after SD with aprotinin at the concentration of 0, 100, 250, 500, and 1000 kIU/mL. *P < .05, **P < .01, ***P < .001 versus aprotinin 0 kIU/mL by ANOVA with Bonferroni comparisons. Data are shown as means ± standard error of the mean (n = 6-8). AP, Aprotinin. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 1939-1945DOI: (10.1016/j.jtcvs.2013.09.054) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions